Gestational phthalate exposure and lung function during childhood: A prospective population-based study

Magda Bosch de Basea1, Anne-Elie Carsin2, Alicia Abellan3

  • 1Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Insights

Gestational exposure to phthalates may negatively impact children's lung function, specifically reducing forced vital capacity (FVC) and forced expiratory volume (FEV1). This association was observed throughout childhood, particularly in early years, highlighting the need for phthalate exposure regulations.

Area of Science:

  • Environmental Health
  • Pediatric Pulmonology
  • Toxicology

Background:

  • Phthalate exposure during pregnancy is widespread.
  • The impact of prenatal phthalate exposure on childhood lung function remains unclear.
  • Phthalates are known endocrine disruptors with potential health implications for children.

Purpose of the Study:

  • To investigate the association between gestational phthalate exposure and lung function in children from ages 4 to 11.
  • To assess phthalate effects on forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) over time.
  • To evaluate individual and mixture effects of phthalate metabolites on respiratory health.

Main Methods:

  • Measured 9 phthalate metabolites in urine from 641 pregnant women (INMA study, Spain).
  • Assessed offspring lung function (FVC, FEV1, FEV1/FVC) at ages 4, 7, 9, and 11.
  • Employed linear regression, mixed-effects models, and Weighted Quantile Sum (WQS) regression for statistical analysis.

Main Results:

  • Gestational phthalate exposure was consistently linked to lower FVC and FEV1 in children across all ages.
  • Specific phthalate metabolites like MEP, MiBP, MnBP, and MBzP showed statistically significant associations with reduced lung function.
  • WQS regression identified MBzP as a key contributor to the mixture effect of phthalates on lung function.

Conclusions:

  • Prenatal phthalate exposure is associated with diminished lung function (FVC and FEV1) in children, especially during early childhood.
  • Findings support the significance of phthalate metabolites like MEP, MiBP, MnBP, and MBzP in affecting respiratory development.
  • The results underscore the importance of current regulations limiting phthalate exposure due to their widespread presence and endocrine-disrupting properties.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
Types of Toxins01:36

Types of Toxins

Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
1.9K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
171